Phase 1 Brain Cancer Trial, Recruiting NCT06176066 Sponsor: University of California, Los Angeles Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT06176066
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who are able to give written consent to participate, and who are able to follow the study requirements
  • People who have a good general level of functioning, as measured by a standard medical scale called the Karnofsky Performance Scale (score above 70) (confirm with trial site)
  • People who have a suspected, newly diagnosed, or returning brain tumour that is likely to be a specific type called IDH wild-type WHO Grade IV glioblastoma, based on brain imaging reviewed by a specialist radiology team

Who may not be able to join:

  • People under 18 years of age
  • People who have a health condition or abnormality that the study doctor believes could put them at risk or affect the reliability of the study results
  • People who are not medically cleared to undergo open brain surgery (specifically a procedure to remove a tumour, not just a biopsy), based on standard pre-surgical guidelines
  • People whose tumour is located in, or clearly affecting, certain critical areas of the brain — including areas that control movement, sensation, language (such as Broca's and Wernicke's areas), or the nerve fibres connecting these areas, as identified on specialised brain scans

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
5 August 2025
Est. completion
1 July 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Resection limiting toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov